基线尿骨桥蛋白水平与代谢综合征的改善相关。
Baseline urinary osteopontin levels are associated with the improvement of metabolic syndrome.
机构信息
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy.
First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, Genoa, Italy; IRCCS Ospedale Policlinico San Martino, Genoa - Italian Cardiovascular Network, Genoa, Italy.
出版信息
Nutr Metab Cardiovasc Dis. 2024 Aug;34(8):1874-1878. doi: 10.1016/j.numecd.2024.03.028. Epub 2024 Mar 29.
BACKGROUND AND AIMS
While serum osteopontin (OPN)'s established role in cardiometabolic risk is recognized, its potential as a predictor of metabolic syndrome (MetS) improvement through a urine assay has not yet been demonstrated. In this study, we propose its potential predictive role over a 12-month period of standard care, with the ability to complement anthropometric measures.
METHODS AND RESULTS
Hierarchical clustering revealed a notable association of urinary OPN (uOPN) with MetS criteria and overcame anthropometric measures in predicting the improvement at 12 months (OR of 2.74 [95% CI 1.32 to 6.29]). uOPN significantly contributed to the homogeneity of the nodes in the random forest and ultimately enhanced the performance of anthropometric measures when assessed for accuracy and area under the curve (AUC).
CONCLUSION
Our findings offer insights into potential applications in cardiometabolic medicine for uOPN, which is easily detectable in non-invasive biological samples through an affordable assay.
背景与目的
尽管血清骨桥蛋白（OPN）在心脏代谢风险中的作用已得到证实，但通过尿液检测其作为代谢综合征（MetS）改善的预测因子的潜力尚未得到证实。在这项研究中，我们提出了在标准治疗 12 个月期间，其具有潜在的预测作用，并能够补充人体测量学指标。
方法和结果
层次聚类显示尿骨桥蛋白（uOPN）与 MetS 标准有显著关联，并在预测 12 个月时的改善方面克服了人体测量学指标（OR 为 2.74[95%CI 1.32 至 6.29]）。uOPN 显著增加了随机森林中节点的同质性，最终提高了人体测量学指标的准确性和曲线下面积（AUC）。
结论
我们的研究结果为 uOPN 在心脏代谢医学中的潜在应用提供了新的见解，通过负担得起的检测方法，uOPN 可以在非侵入性生物样本中很容易地检测到。
Zotero 插件